
Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine. She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.
Education and Training
- Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
- Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
- Medical Resident, Medicine, Duke University, 2002 - 2005
- M.D., Johns Hopkins University, 2002
Grants
- Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
- Interdisciplinary Research Training Program in AIDS
- VTEU 14-0053 Task C Option 2 Protocol Implementation
- Molecular Mycology and Pathogenesis Training Program
- TDE Pickett Road Infrastructure
- Unified Program for Therapeutics in Children
- VTEU: Task Area D: Research Laboratory Analysis Protocol #14-0053
- VTEU 14-0053 Task C Option 4 Protocol Implementation
- ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
- Randomized Trial to Prevent Vascular Events in HIV- REPRIEVE (A5332)
- HERO Program, HERO Registry, HERO-HCQ Trial
- Identification of Novel Bioactive Lipid Metabolites for Predicting Liver-related Outcomes in Persons Co-Infected with HIV and HCV (R01)
- Ancillary Studies of NAFLD and NASH in HIV infected Adults (R01)
- EPCTU - Task Area A - Admin and Overall
- A Multidisciplinary Approach to Primary Cardiovascular Disease Prevention in HIV-infected (K23)
- Leadership and Operations Center (LOC) AIDS Clinical Trials Group (ACTG) Protocol Chair Support for A5380
- Rapid diagnosis and quantification of HIV by direct capture, labelling and detection of individual virions
- Duke Resident Physician-Scientist Program - NIAID
- NIAID Virology Quality Assurance - Year 3 Option 2